Ten years evaluation of epidemiology- and mortality-related factors in adults and children with Guillain-Barré syndrome in the north of Iran

Background: Guillain-Barré Syndrome (GBS) is an autoimmune disease that may occur after infections. As Coronavirus Disease 2019 (COVID-19) may bring about GBS, it is important to assess the effect of the COVID-19 pandemic on this disease Objectives: This study aimed to compare the distribution and characteristics of GBS during and before the COVID-19 pandemic in an academic referral hospital in the north of Iran. Materials & Methods: This retrospective study assessed GBS distribution and characteristics during the COVID-19 pandemic period (from March 2020 to the end of February 2021) and before the pandemic (from March 2019 to the end of February 2020) on 5340 patients referred to the Neurology Ward of Poursina Hospital of Guilan Province, in Iran. Results: There was no significant difference between GBS distribution during (0.03%) and before (0.04%) the COVID-19 pandemic (P=0.413). There were also no differences between the two periods regarding the gender (P=0.659) and age (P=0.417) of the patients. The most common subtype of GBS during the COVID-19 pandemic was Acute Motor and Sensory Axonal Neuropathy (AMSAN) (71.4%). In both periods, the most common type of treatment was intravenous administration of immune globulin. There was no significant difference between the two periods (P=0.838) regarding the patients’ treatment response. Conclusion: The distribution of GBS, its subtypes, type of treatment, and response to treatment were not different between the two study periods.

Download Full-text

High-Dose Intravenous Immune Globulin in the Management of Severe Guillain-Barre Syndrome

Annals of Pharmacotherapy ◽

10.1177/106002809202600108 ◽

1992 ◽

Vol 26 (1) ◽

pp. 32-33 ◽

Cited By ~ 5

Author(s):

Miguel Urtasun ◽

Adolfo López de Murrain ◽

Nieves Carrera ◽

José F. Martí-Massó ◽

Gonzalo López de Dicastillo ◽

...

Keyword(s):

Ad Hoc ◽

Care Center ◽

Tertiary Care ◽

Final Analysis ◽

Multicenter Trial ◽

Guillain Barre Syndrome ◽

High Dose ◽

The North ◽

Guillain Barré Syndrome ◽

Guillain Barré

OBJECTIVE: To evaluate the efficacy of high-dose intravenous gammaglobulin (IGIV) versus plasmapheresis in patients with severe Guillain-Barré syndrome (GBS) and compare the costs of both treatments. DESIGN: Retrospective review of all severely disabled GBS patients admitted between January 1 and December 31, 1990. SETTING: Neurologic unit of a tertiary-care center. PATIENTS: Six patients fulfilling the criteria for the diagnosis of GBS agreed upon by the ad hoc National Institute of Neurological and Communicative Disorders and Stroke committee. INTERVENTION: Four patients treated with plasmapheresis underwent three to six sessions of plasma exchange. Two patients received IGIV 0.4 g/kg/d administered over a five-day period. MAIN OUTCOME MEASURES: Recovery time, functional assessment (performed according to the grading scale used in the North American trial) at 30, 60, and 90 days after treatment. Cost of plasmapheresis, IGIV, and bed/day were compared. RESULTS: Clinical recovery appeared to be faster and more complete in the IGIV group than in the plasmapheresis group. No adverse reactions related to IGIV treatment appeared. The total cost was greater in the plasmapheresis group. CONCLUSIONS: These preliminary results suggest that IGIV may be more beneficial and less expensive than plasmapheresis in treatment of GBS. Definitive conclusions regarding the efficacy of IGIV in GBS will need to await the final analysis of the Ducht randomized multicenter trial comparing IGIV with plasmapheresis.

Download Full-text

The north American study of plasmapheresis in the guillain-barre syndrome

Journal of Clinical Apheresis ◽

10.1002/jca.2920020416 ◽

1985 ◽

Vol 2 (4) ◽

pp. 315-320 ◽

Cited By ~ 5

Author(s):

Keyword(s):

North American ◽

Guillain Barre Syndrome ◽

American Study ◽

North American Study ◽

The North ◽

Guillain Barré Syndrome ◽

Guillain Barré

Download Full-text

Updates in the management of Guillain Barre Syndrome

Anaesthesia, Pain & Intensive Care ◽

10.35975/apic.v22i1.1102 ◽

2019 ◽

pp. S54-S57

Author(s):

Novi Chandra Imelda ◽

Fadil Baktir ◽

Fidiana . ◽

Hanik Badriyah Hidayati ◽

Mudjiani Basuki

Keyword(s):

Intensive Care ◽

Ivig Therapy ◽

Good Prognosis ◽

Clinical Syndrome ◽

Guillain Barre Syndrome ◽

Related Factors ◽

Immunological Mechanism ◽

Hospital Units ◽

Guillain Barré Syndrome ◽

Guillain Barré

Barré and Strohl in 1916. Although GBS has a good prognosis (5% mortality rate), about 10% of patients experience serious disability one year after the start of neurological onset. Recent research of GBS shows that the process involves a number of subtypes with different immunological mechanism and a spectrum of clinical syndrome of acute inflammatory neuropathy. Antibodies against peripheral nerve gangliosides and their own complements are recognized as an important mechanism of nerve damage in GBS. Pharmacokinetics of intravenous immunoglobulin (IVIg) therapy and other related factors that influence prognosis has been researched. In order to investigate the possible role of complement inhibition in GBS management, new studies will be conducted. The management of GBS should be provided in appropriate hospital units, with specialist teams, intensive care and rehabilitation facilities as essential parts. This article aims to provide updated management of GBS.Citation: Imelda NC, Baktir F, Fidiana, Hidayati HB, Basuki M. Updates in the management of Guillain Barre Syndrome. Anaesth Pain & Intensive Care 2018;22 Suppl 1:S54-S57

Download Full-text